Orion - Major shareholder announcements

Disclosure Under Chapter 2 Section 10

ORION CORPORATION STOCK EXCHANGE RELEASE 7 November 2011 at
12:40 EET
Orion Corporation (business code 1999212-6) has received a disclosure under
Chapter 2, Section 9 of the Securities Markets Act, according to which the total
number of the voting rights of the Orion shares owned by Erkki Etola and a
company controlled by him, has in consequence of the share conversion under the
Articles of Association of Orion Corporation executed on 7 November 2011
exceeded the one twentieth (1/20) threshold of the total number of Orion
Corporation voting rights.

The total holding of  Erkki Etola and the company controlled by him according to
the disclosure (percentages rounded):

Share type         Number of shares Percent (%) of Percent (%)
                                    total shares   voting rights

A share            2,500,000        1.77           5.00

ISIN:FI0009014369

    Etola Oy       2,300,000        1.63           4.60

    Erkki Etola       200,000       0.14           0.40

B share            0                0              0

ISIN:FI0009014377

Total              2,500,000        1.77           5.00


Orion Corporation's share capital comprises 141,257,828 shares, of which
45,194,218 are A shares and 96,063,610 are B shares. Each A share entitles its
holder to twenty (20) votes and each B share to one (1) vote. Thus, the total
number of votes is 999,947,970.

Orion Corporation



Timo Lappalainen                       Olli Huotari
President and CEO                    SVP, Corporate Functions

Contact person:
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi

Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler®
pulmonary drugs.

The Group's net sales in 2010 amounted to EUR 850 million. The Company invested
EUR 85 million in research and development. At the end of 2010, the Group had a
total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650
in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1561347]